Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

NCT02299570 is registered in ClinicalTrials.gov with Rebiotix Inc. as lead sponsor.

NCT NCT02299570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02299570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Lead sponsor
Rebiotix Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
January 31, 2018
Enrollment
150 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

enterocolitis clostridium difficile recurrent